Fall 2010 issue
Biotechnology Healthcare "Oncology Biomarker Diagnostics: Where We Are, Where We Need To Be" This wide-ranging article examines the reasons behind the relatively low number of commercialized diagnostic products in oncology. Catalyst President Nancy Bradish Myers comments on the potential impact of an upcoming guidance from FDA's Center for Devices and Radiological Health. She also comments